Sooma Receives Breakthrough Status for At-Home Depression Treatment Device
Finland-based Sooma Medical has been granted FDA Breakthrough Device status for its portable at-home neuromodulation device to treat depression.
The device uses a non-invasive mild electrical current to stimulate targeted brain areas to improve depressive symptoms.
The treatment, which can be stand-alone or used in combination with drug therapy, consists of daily 30-minute sessions for a minimum of three weeks.
Most patients see results around the third week of treatment, the company said. According to Sooma's post-market data, more than half of patients achieve a complete clinical response in their depressive symptoms after the treatment.
The FDA's breakthrough designation is for novel therapies that show significant potential to provide a substantial improvement over existing options for severe or life-threatening conditions.
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May